Abstract
Easily screening markers for early detection of chronic heart failure (CHF) are lacking. We identified twenty differently expressed proteins including orosomucoid 1(ORM1) in urine between patients with CHF and normal controls by proteomic methods. Bioinformatics analyses suggested ORM1 could be used for further analysis. After verification by western blotting, the urinary levels of ORM1 were quantified with enzyme-linked immunosorbent assay (ELISA) by correcting for creatinine expression. The ORM1-Cr was significantly elevated in CHF patients than normal controls (6498.83±4300.21 versus 2102.26±1069.24 ng/mg). Furthermore, a Spearman analysis indicated that the urinary ORM1 levels had a high positive correlation with the classification of CHF, and the multivariate analysis suggested that the urinary ORM1 content was associated with the plasma amino-terminal pro- brain natriuretic peptide (NT-proBNP) (OR: 2.106, 95% CI: 1.213–3.524, P = 0.002) and the New York Heart Association (NYHA) classification (OR: 3.019, 95% CI: 1.329–4.721, P<0.001). In addition, receiving operating curve (ROC) analyses suggested that an optimum cut-off value of 2484.98 ng/mg with 90.91% sensitivity and 85.48% specificity, respectively, could be used for the diagnosis of CHF. To sum up, our findings indicate that ORM1 could be a potential novel urinary biomarker for the early detection of CHF.
Highlights
Chronic heart failure (CHF), a clinical syndrome of left ventricular systolic and/or diastolic dysfunction, remains a major threat to public health [1]
We suggest that orosomucoid 1 (ORM1) is a potential novel urinary biomarker for the early detection of CHF
Cardiac function for each CHF patient was divided into class II, class III, and class IV according to the Cardiac Function Standard of the New York Heart Association (NYHA)
Summary
Chronic heart failure (CHF), a clinical syndrome of left ventricular systolic and/or diastolic dysfunction, remains a major threat to public health [1]. It has been estimated that there are currently over 5 million CHF patients, and more than 550,000 new patients diagnosed yearly in the USA [2]. Many CHF patients do not receive accurate diagnoses or optimum pharmacological treatments, resulting in substantial mortality and morbidity. Great progress has been made in diagnostic intensity and treatment, the long-term prognosis for CHF is still poor. The rising incidence of CHF is a cause for concern, and there is currently no gold standard for its diagnosis [4]. Diagnosis and treatment are extremely important in this disease. The development of a reliable, non-invasive biomarker is of considerable clinical importance, aiming at increasing the early detection rate of heart failure and/or predicting the progression of the disease in time
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
